Personalized cancer immunotherapy using Systems Medicine approaches

The immune system is by definition multi-scale because it involves biochemical networks that regulate cell fates across cell boundaries, but also because immune cells communicate with each other by direct contact or through the secretion of local or systemic signals. Furthermore, tumor and immune cells communicate, and this interaction is affected by the tumor microenvironment. Altogether, the tumor-immunity interaction is a complex multi-scale biological system whose analysis requires a systemic view to succeed in developing efficient immunotherapies for cancer and immune-related diseases. In this review we discuss the necessity and the structure of a systems medicine approach for the design of anticancer immunotherapies. We support the idea that the approach must be a combination of algorithms and methods from bioinformatics and patient-data-driven mathematical models conceived to investigate the role of clinical interventions in the tumor-immunity interaction. For each step of the integrative approach proposed, we review the advancement with respect to the computational tools and methods available, but also successful case studies. We particularized our idea for the case of identifying novel tumor-associated antigens and therapeutic targets by integration of patient's immune and tumor profiling in case of aggressive melanoma.

[1]  G. Rose,et al.  Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Gajendra P. S. Raghava,et al.  AlgPred: prediction of allergenic proteins and mapping of IgE epitopes , 2006, Nucleic Acids Res..

[3]  Ira Mellman,et al.  Designing vaccines based on biology of human dendritic cell subsets. , 2010, Immunity.

[4]  Yanxin Huang,et al.  Conformational B-Cell Epitope Prediction Method Based on Antigen Preprocessing and Mimotopes Analysis , 2015, BioMed research international.

[5]  Shoba Ranganathan,et al.  Modeling the structure of bound peptide ligands to major histocompatibility complex , 2004, Protein science : a publication of the Protein Society.

[6]  M. Sadelain,et al.  Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma , 2012 .

[7]  Vladimir Brusic,et al.  Predictive Vaccinology: Optimisation of Predictions Using Support Vector Machine Classifiers , 2005, IDEAL.

[8]  M. Wirth,et al.  Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer , 2012, Cancers.

[9]  Magdalini Moutaftsi,et al.  A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.

[10]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[11]  Ellis L. Reinherz,et al.  Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles , 2004, Immunogenetics.

[12]  Vasant G Honavar,et al.  Predicting linear B‐cell epitopes using string kernels , 2008, Journal of molecular recognition : JMR.

[13]  F. Marincola,et al.  gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.

[14]  Shishir K. Gupta,et al.  In silico accelerated identification of structurally conserved CD8+ and CD4+ T-cell epitopes in high-risk HPV types. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[15]  Andrew J. G. Simpson,et al.  CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens , 2008, Nucleic Acids Res..

[16]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[17]  V. Brusic,et al.  Bioinformatics for cancer immunotherapy target discovery , 2014, Cancer Immunology, Immunotherapy.

[18]  Tilo Beyer,et al.  Integrating Signals from the T-Cell Receptor and the Interleukin-2 Receptor , 2011, PLoS Comput. Biol..

[19]  Shishir K. Gupta,et al.  In silico CD4+ T-cell epitope prediction and HLA distribution analysis for the potential proteins of Neisseria meningitidis Serogroup B--a clue for vaccine development. , 2010, Vaccine.

[20]  D. Flower,et al.  Peptide binding to the HLA-DRB1 supertype: a proteochemometrics analysis. , 2010, European journal of medicinal chemistry.

[21]  P. Srivastava,et al.  Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges , 2013, Cancer Immunology, Immunotherapy.

[22]  Jérôme Lane,et al.  IMGT®, the international ImMunoGeneTics information system® , 2004, Nucleic Acids Res..

[23]  Xinglong Yu,et al.  An introduction to epitope prediction methods and software , 2009, Reviews in medical virology.

[24]  M. Socinski,et al.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[25]  Bart Spiessens,et al.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  O. Wolkenhauer,et al.  Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network. , 2013, Cancer research.

[27]  Peter P. Lee,et al.  Modeling Protective Anti-Tumor Immunity via Preventative Cancer Vaccines Using a Hybrid Agent-based and Delay Differential Equation Approach , 2012, PLoS Comput. Biol..

[28]  Weijing Sun,et al.  Cancer immunotherapy in clinical practice—the past, present, and future , 2014, Chinese journal of cancer.

[29]  Ping Zhang,et al.  Searching of optimal vaccination schedules , 2009, IEEE Engineering in Medicine and Biology Magazine.

[30]  Tin Wee Tan,et al.  Methods and protocols for prediction of immunogenic epitopes , 2006, Briefings Bioinform..

[31]  Pornpimol Charoentong,et al.  Bioinformatics for cancer immunology and immunotherapy , 2012, Cancer Immunology, Immunotherapy.

[32]  B. A. Jameson,et al.  The antigenic index: a novel algorithm for predicting antigenic determinants , 1988, Comput. Appl. Biosci..

[33]  Francesco Pappalardo,et al.  Modeling the competition between lung metastases and the immune system using agents , 2010, BMC Bioinformatics.

[34]  A. Alix,et al.  Predictive estimation of protein linear epitopes by using the program PEOPLE. , 1999, Vaccine.

[35]  Wei Li,et al.  ElliPro: a new structure-based tool for the prediction of antibody epitopes , 2008, BMC Bioinformatics.

[36]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[37]  U. Klein,et al.  Article Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of Irf4 , 2022 .

[38]  Byung-Jun Yoon,et al.  Hidden Markov Models and their Applications in Biological Sequence Analysis , 2009, Current genomics.

[39]  Shishir K. Gupta,et al.  Understanding the Mechanism of Atovaquone Drug Resistance in Plasmodium falciparum Cytochrome b Mutation Y268S Using Computational Methods , 2014, PloS one.

[40]  P. Canoll,et al.  Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma , 2012, Journal of Clinical Neuroscience.

[41]  J. Rothbard,et al.  Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. , 1994, Journal of immunology.

[42]  Pierre Baldi,et al.  COBEpro: a novel system for predicting continuous B-cell epitopes. , 2009, Protein engineering, design & selection : PEDS.

[43]  Fenglin Lv,et al.  Toward prediction of binding affinities between the MHC protein and its peptide ligands using quantitative structure-affinity relationship approach. , 2008, Protein and peptide letters.

[44]  Vladimir Brusic,et al.  Prediction of promiscuous peptides that bind HLA class I molecules , 2002, Immunology and cell biology.

[45]  Pingping Guan,et al.  EpiJen: a server for multistep T cell epitope prediction , 2006, BMC Bioinformatics.

[46]  H. Pehamberger,et al.  High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells , 2005, Cancer Immunology, Immunotherapy.

[47]  J. Agrewala,et al.  In silico methods for predicting T-cell epitopes: Dr Jekyll or Mr Hyde? , 2009, Expert review of proteomics.

[48]  K. Chou,et al.  Prediction of linear B-cell epitopes using amino acid pair antigenicity scale , 2007, Amino Acids.

[49]  Minoru Kanehisa,et al.  MIMOX: a web tool for phage display based epitope mapping , 2006, BMC Bioinformatics.

[50]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[51]  F. Brasseur,et al.  A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma , 1996, The Journal of experimental medicine.

[52]  David A. Lee,et al.  Predicting protein function from sequence and structure , 2007, Nature Reviews Molecular Cell Biology.

[53]  H Mamitsuka,et al.  Predicting peptides that bind to MHC molecules using supervised learning of hidden markov models , 1998, Proteins.

[54]  T. Elliott,et al.  Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. , 2000, Tissue antigens.

[55]  Marialva Sinigaglia,et al.  CrossTope: a curate repository of 3D structures of immunogenic peptide: MHC complexes , 2013, Database J. Biol. Databases Curation.

[56]  C. Chelala,et al.  A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws , 2011, Nucleic acids research.

[57]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[58]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[59]  John Sidney,et al.  Predicting population coverage of T-cell epitope-based diagnostics and vaccines , 2006, BMC Bioinformatics.

[60]  Søren Buus,et al.  Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding , 1996, European journal of immunology.

[61]  Gajendra P. S. Raghava,et al.  SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence , 2004, Bioinform..

[62]  O. Wolkenhauer,et al.  Envisioning the Application of Systems Biology in Cancer Immunology , 2020, Cancer Immunology.

[63]  I. Haworth,et al.  Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design. , 2007, Journal of molecular graphics & modelling.

[64]  Grant Lythe,et al.  How many dendritic cells are required to initiate a T-cell response? , 2012, Blood.

[65]  Paul François,et al.  Phenotypic model for early T-cell activation displaying sensitivity, specificity, and antagonism , 2013, Proceedings of the National Academy of Sciences.

[66]  D. Flower,et al.  QSAR and the Prediction of T-Cell Epitopes , 2008 .

[67]  C. Wheeler,et al.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[68]  N. Hacohen,et al.  HLA-Binding Properties of Tumor Neoepitopes in Humans , 2014, Cancer Immunology Research.

[69]  K. Akashi,et al.  Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study , 2015, British journal of haematology.

[70]  Alessandro Sette,et al.  The Immune Epitope Database 2.0 , 2009, Nucleic Acids Res..

[71]  H. Margalit,et al.  Sequence features that correlate with MHC restriction. , 1994, Molecular immunology.

[72]  J. Slansky,et al.  Improving T cell responses to modified peptides in tumor vaccines , 2012, Immunologic Research.

[73]  H. Rammensee,et al.  The making of the dominant MHC class I ligand SYFPEITHI , 1998, European journal of immunology.

[74]  K. Choudhury,et al.  Precision Cancer Immunotherapy: Optimizing Dendritic Cell-based Strategies to Induce Tumor Antigen-specific T-cell Responses Against Individual Patient Tumors , 2015, Journal of immunotherapy.

[75]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[76]  J. Becker,et al.  Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma , 2012, Cancer Immunology, Immunotherapy.

[77]  F. Rojo,et al.  Pharmacodynamics: biological activity of targeted therapies in clinical trials , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[78]  Cliburn Chan,et al.  Feedback control of T–cell receptor activation , 2004, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[79]  Yuri Kogan,et al.  Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models , 2010, PloS one.

[80]  Z. Trajanoski,et al.  Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer , 2014, Cancer Immunology, Immunotherapy.

[81]  Pietro Liò,et al.  Trends in modeling Biomedical Complex Systems , 2009, BMC Bioinformatics.

[82]  Vasant Honavar,et al.  Recent advances in B-cell epitope prediction methods , 2010, Immunome research.

[83]  Yingdong Zhao,et al.  Application of support vector machines for T-cell epitopes prediction , 2003, Bioinform..

[84]  Y. Li,et al.  An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signaling , 2011, Molecular systems biology.

[85]  Wei-Feng Xu,et al.  PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response , 1999, Cell Research.

[86]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[87]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[88]  S. Gupta,et al.  Ethnicity-tailored novel set of ESAT-6 peptides for differentiating active and latent tuberculosis. , 2013, Tuberculosis.

[89]  J. Sidney,et al.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity , 2014, The Journal of experimental medicine.

[90]  P. Karplus,et al.  Prediction of chain flexibility in proteins , 1985, Naturwissenschaften.

[91]  Z. Nagy,et al.  Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.

[92]  Nathalie Vigneron,et al.  Database of T cell-defined human tumor antigens: the 2013 update. , 2013, Cancer immunity.

[93]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[94]  S. Ferrone,et al.  Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects , 2006, The Journal of Immunology.

[95]  Y. Kogan,et al.  Improving T-cell Immunotherapy for Melanoma Through a Mathematically Motivated Strategy: Efficacy in Numbers? , 2012, Journal of immunotherapy.

[96]  F Castiglione,et al.  Cancer immunotherapy, mathematical modeling and optimal control. , 2007, Journal of theoretical biology.

[97]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[98]  Julio Vera,et al.  Optimization of biochemical systems through mathematical programming: Methods and applications , 2010, Comput. Oper. Res..

[99]  J A Sherratt,et al.  Pattern formation and spatiotemporal irregularity in a model for macrophage-tumour interactions. , 1997, Journal of theoretical biology.

[100]  Zhide Hu,et al.  QSAR method for prediction of protein-peptide binding affinity: application to MHC class I molecule HLA-A*0201. , 2007, Journal of molecular graphics & modelling.

[101]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[102]  E. Jaffee,et al.  The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.

[103]  Martin A. Cheever,et al.  PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine , 2011, Clinical Cancer Research.

[104]  James Robinson,et al.  IPD—the Immuno Polymorphism Database , 2004, Nucleic acids research.

[105]  O. Lund,et al.  Prediction of residues in discontinuous B‐cell epitopes using protein 3D structures , 2006, Protein science : a publication of the Protein Society.

[106]  Bashir A Akhoon,et al.  In silico designing and optimization of anti-breast cancer antibody mimetic oligopeptide targeting HER-2 in women. , 2010, Journal of molecular graphics & modelling.

[107]  L. Billingham,et al.  Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma , 2011, Gene Therapy.

[108]  P. Barker,et al.  Efficient Generation of Major Histocompatibility Complex Class I-Peptide Complexes Using Synthetic Peptide Libraries* , 1998, The Journal of Biological Chemistry.

[109]  Timothy J. Lavelle,et al.  Immunological network signatures of cancer progression and survival , 2011, BMC Medical Genomics.

[110]  Joakim Dillner,et al.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.

[111]  K. R. Woods,et al.  Prediction of protein antigenic determinants from amino acid sequences. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[112]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[113]  Morten Nielsen,et al.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..

[114]  A. Radunskaya,et al.  A Model of Dendritic Cell Therapy for Melanoma , 2013, Front. Oncol..

[115]  Anne S De Groot,et al.  Bioinformatics tools for identifying class I-restricted epitopes. , 2003, Methods.

[116]  H. Bui,et al.  Structural prediction of peptides binding to MHC class I molecules , 2006, Proteins.

[117]  E Westhof,et al.  Correlation between the location of antigenic sites and the prediction of turns in proteins. , 1993, Immunology letters.

[118]  Johannes Söllner,et al.  Selection and combination of machine learning classifiers for prediction of linear B‐cell epitopes on proteins , 2006, Journal of molecular recognition : JMR.

[119]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[120]  Olaf Wolkenhauer,et al.  Integration of sensitivity and bifurcation analysis to detect critical processes in a model combining signalling and cell population dynamics , 2010, Int. J. Syst. Sci..

[121]  Syed Haider,et al.  International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data , 2011, Database J. Biol. Databases Curation.

[122]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[123]  Yuri Kogan,et al.  Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. , 2012, Cancer research.

[124]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[125]  P. Tighe,et al.  Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine , 1995, Clinical molecular pathology.

[126]  B. Schoeberl,et al.  MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors , 2013, Molecular Cancer Therapeutics.

[127]  James Robinson,et al.  The IPD and IMGT/HLA database: allele variant databases , 2014, Nucleic Acids Res..

[128]  D. Bowtell,et al.  A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. , 2012, Cancer research.

[129]  Irini Doytchinova,et al.  EpiDOCK: a molecular docking-based tool for MHC class II binding prediction. , 2013, Protein engineering, design & selection : PEDS.

[130]  Ping Zhu,et al.  MimoDB 2.0: a mimotope database and beyond , 2011, Nucleic Acids Res..

[131]  M. Zanetti Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics , 2015, The Journal of Immunology.

[132]  K. Kohn,et al.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.

[133]  Vladimir Brusic,et al.  Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network , 1998, Bioinform..

[134]  Doron Levy,et al.  A Mathematical Model of the Enhancement of Tumor Vaccine Efficacy by Immunotherapy , 2012, Bulletin of mathematical biology.

[135]  Ruo-Pan Huang,et al.  Tumor-induced perturbations of cytokines and immune cell networks. , 2014, Biochimica et biophysica acta.

[136]  Rick Reitmaier,et al.  Review of immunoinformatic approaches to in-silico B-cell epitope prediction , 2007 .

[137]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[138]  B. McMahon,et al.  Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. , 2007, Vaccine.

[139]  D. Madden The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.

[140]  F. Pappalardo,et al.  In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.

[141]  Wei Zhang,et al.  Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies , 2013, BMC Biotechnology.

[142]  H. Kalbacher,et al.  New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. , 1996, European journal of biochemistry.

[143]  S. Rosenberg,et al.  T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product , 2004, The Journal of Immunology.

[144]  Kun Yu,et al.  Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study , 2002, Molecular medicine.

[145]  Gajendra P.S. Raghava,et al.  A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes , 2007, Journal of Biosciences.

[146]  T. Lundstedt,et al.  Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. , 2001, Biochimica et biophysica acta.

[147]  Irini Doytchinova,et al.  T-cell epitope vaccine design by immunoinformatics , 2013, Open Biology.

[148]  S. Tenzer,et al.  Using the World Wide Web for predicting CTL epitopes. , 2003, Current opinion in immunology.

[149]  L Raddrizzani,et al.  In Vitro and In Vivo Induction of a Th Cell Response Toward Peptides of the Melanoma-Associated Glycoprotein 100 Protein Selected by the TEPITOPE Program1 , 2000, The Journal of Immunology.

[150]  Naoki Abe,et al.  Prediction of MHC Class I Binding Peptides by a Query Learning Algorithm Based on Hidden Markov Models , 2002, Journal of biological physics.

[151]  Q. Xia,et al.  Quantitative prediction of class I MHC/epitope binding affinity using QSAR modeling derived from amino acid structural information. , 2015, Combinatorial chemistry & high throughput screening.

[152]  J. Thornton,et al.  Continuous and discontinuous protein antigenic determinants , 1986, Nature.

[153]  C. Watzl,et al.  Understanding natural killer cell regulation by mathematical approaches , 2012, Front. Immun..

[154]  A. d’Onofrio A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.

[155]  N. Shastri,et al.  Non-conventional sources of peptides presented by MHC class I , 2011, Cellular and Molecular Life Sciences.

[156]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.